Knight Therapeutics (TSE:GUD) Price Target Raised to C$7.45 at Stifel Nicolaus

Knight Therapeutics (TSE:GUD - Get Free Report) had its price target increased by equities research analysts at Stifel Nicolaus from C$6.25 to C$7.45 in a research note issued to investors on Tuesday,BayStreet.CA reports. The firm currently has a "buy" rating on the stock. Stifel Nicolaus' target price would suggest a potential upside of 22.33% from the company's previous close.

Other research analysts have also recently issued reports about the company. Research Capitl upgraded Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, March 11th. Canaccord Genuity Group downgraded Knight Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, March 21st. One investment analyst has rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of C$7.48.

Knight Therapeutics Stock Up 1.5 %

Shares of Knight Therapeutics stock traded up C$0.09 during trading hours on Tuesday, reaching C$6.09. 58,415 shares of the company were exchanged, compared to its average volume of 70,839. The firm has a market cap of C$616.00 million, a PE ratio of -20.33, a PEG ratio of -1,013.50 and a beta of 0.50. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. Knight Therapeutics has a 1 year low of C$5.09 and a 1 year high of C$6.45. The stock's fifty day moving average is C$5.74 and its 200 day moving average is C$5.60.

Remove Ads

Insider Buying and Selling

In other Knight Therapeutics news, insider Sime Armoyan bought 17,600 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average price of C$5.48 per share, for a total transaction of C$96,488.48. Over the last quarter, insiders sold 3,143,300 shares of company stock worth $19,733,740. Corporate insiders own 45.62% of the company's stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.